<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7418</journal-id>
<journal-title><![CDATA[Revista Colombiana de Ciencias Químico - Farmacéuticas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. cienc. quim. farm.]]></abbrev-journal-title>
<issn>0034-7418</issn>
<publisher>
<publisher-name><![CDATA[Departamento de Farmácia, Facultad de Ciencias, Universidade Nacional da Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74182020000100101</article-id>
<article-id pub-id-type="doi">10.15446/rcciquifa.v49n1.85168</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Use of statins and the risk of developing pre-diabetes and diabetes: a longitudinal study in individuals aged 40 years or older]]></article-title>
<article-title xml:lang="pt"><![CDATA[Uso de estatina e risco de desenvolver pré-diabetes e diabetes: um estudo longitudinal em pessoas com 40 anos ou mais]]></article-title>
<article-title xml:lang="es"><![CDATA[Uso de estatinas y el riesgo de desarrollar prediabetes y diabetes: un estudio longitudinal en personas de 40 años o mayores]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Curiaki]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Durán González]]></surname>
<given-names><![CDATA[Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aparecido Sarria Cabrera]]></surname>
<given-names><![CDATA[Marcos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Molino Guidoni]]></surname>
<given-names><![CDATA[Camilo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Girotto]]></surname>
<given-names><![CDATA[Edmarlon]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade Estadual de Londrina  ]]></institution>
<addr-line><![CDATA[Londrina Paraná]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Estadual de Londrina  ]]></institution>
<addr-line><![CDATA[Londrina Paraná]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,https://orcid.org/0000-0003-2965-5062  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af4">
<institution><![CDATA[,https://orcid.org/0000-0002-4203-9400  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af5">
<institution><![CDATA[,https://orcid.org/0000-0001-9786-9674  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af6">
<institution><![CDATA[,https://orcid.org/0000-0001-5844-143X  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af7">
<institution><![CDATA[,https://orcid.org/0000-0001-9345-3348  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<volume>49</volume>
<numero>1</numero>
<fpage>101</fpage>
<lpage>113</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74182020000100101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74182020000100101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74182020000100101&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Background: Statins are the main therapeutic option for the control of dyslipidemias and cardiovascular prevention. However, studies indicate the possibility of the use of statins cause increases in blood glucose levels.  Aim: The aim of the study was to analyze the use of statin and the risk of developing pre-diabetes (DM) or DM.  Methods: This was a cohort study conducted with individuals aged 40 years or older, living in a medium-sized municipality in the north of Paraná, Brazil. Data were obtained through individual interviews and laboratory tests in the years 2011 (baseline) and 2015 (follow-up). Dependent variables were the development of DM (yes; no) and the development of pre-DM or DM (yes; no). The independent variable was the use of statins (no use; use only in 2011; use only in 2015; use in 2011 and 2015). Poisson (loglinear) regression analysis was used to calculate the relative risk (RR) and 95% confidence intervals (95% CI) in generalized linear models.  Results: An association was observed between the use of statins and the incidence of DM (RR 2.89, 95% CI: 1.59-5.24) and the incidence of pre-DM or DM (RR 2.01, 95% CI: 1.39-2.92) for the group of individuals who used statins only in 2015.  Conclusions: The present study identified an association between the use of statins and the incidence of pre-DM and DM only for those who used them exclusively in 2015.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução: As estatinas são a principal opção terapêutica para o controle de dislipidemias e prevenção cardiovascular. No entanto, estudos indicam a possibilidade do uso de estatinas causar aumentos nos níveis de glicose no sangue.  Objetivo: O objetivo do estudo foi analisar o uso de estatina e o risco de desenvolver pré-diabetes (DM) ou DM.  Métodos: Estudo de coorte realizado com indivíduos com 40 anos ou mais de idade, residentes em um município de médio porte no norte do Paraná. Os dados foram obtidos por meio de entrevistas individuais e exames laboratoriais nos anos de 2011 (linha de base) e 2015 (acompanhamento). As variáveis dependentes foram o desenvolvimento de DM (sim; não) e o desenvolvimento de pré-DM ou DM (sim; não). A variável independente foi o uso de estatinas (sem uso; uso apenas em 2011; uso apenas em 2015; uso em 2011 e 2015). A análise de regressão de Poisson (log-linear) foi utilizada para calcular o risco relativo (RR) e os intervalos de confiança de 95% (IC95%) em modelos lineares generalizados.  Resultados: Observou-se associação entre o uso de estatinas e a incidência de DM (RR 2,89, IC 95%: 1,59-5,24) e a incidência de pré-DM ou DM (RR 2,01, IC 95%: 1,39-2,92) para o grupo de indivíduos que usaram estatinas apenas em 2015. Conclusões: O presente estudo identificou associação entre o uso de estatinas e a incidência de pré-DM e DM apenas para aqueles que as usaram exclusivamente em 2015.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: las estatinas son la principal opción terapéutica para el control de la dislipidemia y la prevención cardiovascular. Sin embargo, los estudios indican la posibilidad de que el uso de estatinas pueda causar aumentos en los niveles de glucosa en sangre. Objetivo: analizar el uso de estatinas y el riesgo de desarrollar prediabetes (DM) o DM.  Métodos: estudio de cohorte realizado con individuos de 40 años o más, que viven en un municipio de tamaño medio en el norte de Paraná, Brasil. Los datos se obtuvieron mediante entrevistas individuales y pruebas de laboratorio en los años 2011 (línea de base) y 2015 (seguimiento). Las variables dependientes fueron el desarrollo de DM (sí; no) y el desarrollo de pre-DM o DM (sí; no). La variable independiente fue el uso de estatinas (sin uso; uso solo en 2011; uso solo en 2015; uso en 2011 y 2015). El análisis de regresión de Poisson (log-lineal) se utilizó para calcular el riesgo relativo (RR) y los intervalos de confianza del 95% (IC del 95%) en modelos lineales generalizados.  Resultados: Se observó una asociación entre el uso de estatinas y la incidencia de DM (RR 2,89, IC 95%: 1,59-5,24) y la incidencia de pre-DM o DM (RR 2,01, IC 95%: 1,39-2,92) para el grupo de individuos que usaron estatinas solo en 2015.  Conclusiones: el presente estudio identificó una asociación entre el uso de estatinas y la incidencia de pre-DM y DM solo para aquellos que las usaron exclusivamente en 2015.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[statins]]></kwd>
<kwd lng="en"><![CDATA[adverse drug reactions]]></kwd>
<kwd lng="pt"><![CDATA[Diabetes mellitus]]></kwd>
<kwd lng="pt"><![CDATA[Estatinas]]></kwd>
<kwd lng="pt"><![CDATA[Eventos adversos]]></kwd>
<kwd lng="es"><![CDATA[Diabetes mellitus]]></kwd>
<kwd lng="es"><![CDATA[estatinas]]></kwd>
<kwd lng="es"><![CDATA[evento adverso]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Naghavi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Foreman]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Shibuya]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Aboyans]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<numero>9859</numero>
<issue>9859</issue>
<page-range>2095-128</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Vera]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bhole]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[L.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lacaille]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review]]></article-title>
<source><![CDATA[Br. J. Clin. Pharmacol]]></source>
<year>2014</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>684-98</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baigent]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Blackwell]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Emberson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[L.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Reith]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<numero>9753</numero>
<issue>9753</issue>
<page-range>1670-81</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faludi]]></surname>
<given-names><![CDATA[A.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Izar]]></surname>
<given-names><![CDATA[M.C.O.]]></given-names>
</name>
<name>
<surname><![CDATA[Saraiva]]></surname>
<given-names><![CDATA[J.F.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Chacra]]></surname>
<given-names><![CDATA[A.P.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bianco]]></surname>
<given-names><![CDATA[H.T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Ateroscle-rose-2017]]></article-title>
<source><![CDATA[Arq. Bras. Cardiol]]></source>
<year>2017</year>
<volume>109</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>1-76</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bersot]]></surname>
<given-names><![CDATA[T.P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terapia farmacológica para a hipercolesterolemia e a dislipidemia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Brunton]]></surname>
<given-names><![CDATA[L.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Chabner]]></surname>
<given-names><![CDATA[B.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Knollmann]]></surname>
<given-names><![CDATA[B.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Langeloh]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[As bases farmacológicas da terapêutica de Goodman e Gilman]]></source>
<year>2012</year>
<edition>12</edition>
<page-range>877-908</page-range><publisher-loc><![CDATA[Porto Alegre ]]></publisher-loc>
<publisher-name><![CDATA[AMGH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[E.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rachlis]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Devereaux]]></surname>
<given-names><![CDATA[P.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Arora]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Perri]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65 000 patients]]></article-title>
<source><![CDATA[J. Am. Coll. Cardiol]]></source>
<year>2008</year>
<volume>52</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>1769-81</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Afílalo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Duque]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Steele]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Jukema]]></surname>
<given-names><![CDATA[J.W.]]></given-names>
</name>
<name>
<surname><![CDATA[de Craen]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Eisenberg]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins for secondary prevention in elderly patients: A hierarchical bayesian meta-analysis]]></article-title>
<source><![CDATA[Am. Coll. Cardiol]]></source>
<year>2008</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-45</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brugts]]></surname>
<given-names><![CDATA[J.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Yetgin]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Hoeks]]></surname>
<given-names><![CDATA[S.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Gotto]]></surname>
<given-names><![CDATA[A.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Shepherd]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Westendorp]]></surname>
<given-names><![CDATA[R.G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2009</year>
<volume>338</volume>
<page-range>b2376</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajpathak]]></surname>
<given-names><![CDATA[S.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumbhani]]></surname>
<given-names><![CDATA[D.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Crandall]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Barzilai]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Alderman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ridker]]></surname>
<given-names><![CDATA[P.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin therapy and risk of developing type 2 diabetes: a meta-analysis]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2009</year>
<volume>32</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1924-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Sheen]]></surname>
<given-names><![CDATA[S.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[Y.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[R.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[H.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2016</year>
<volume>95</volume>
<numero>46</numero>
<issue>46</issue>
<publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crandall]]></surname>
<given-names><![CDATA[J.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Mather]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Rajpathak]]></surname>
<given-names><![CDATA[S.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[R.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Foo]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin use and risk of developing diabetes: results from the Diabetes Prevention Program]]></article-title>
<source><![CDATA[BMJ Open Diabetes Res. Care]]></source>
<year>2017</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Preiss]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Seshasai]]></surname>
<given-names><![CDATA[S.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Welsh]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[S.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Waters]]></surname>
<given-names><![CDATA[D.D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2011</year>
<volume>305</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2556-64</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Tett]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Peeters]]></surname>
<given-names><![CDATA[G.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[G.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Dobson]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New-onset diabetes after statin exposure in elderly women: the Australian longitudinal study on women's health]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2017</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>203-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>International Diabetes Federation</collab>
<source><![CDATA[The IDF Diabetes Atlas]]></source>
<year></year>
<edition>8</edition>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[R.K.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Bortoletto]]></surname>
<given-names><![CDATA[M.S.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Loch]]></surname>
<given-names><![CDATA[M.R.]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[A.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuo]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[M.A.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalência de fatores de risco cardiovascular em pessoas com 40 anos ou mais de idade, em Cambé, Paraná (2011), estudo de base populacional]]></article-title>
<source><![CDATA[Epidemiol. Serv. Saude]]></source>
<year>2013</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>435-44</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>Sociedade Brasileira de Diabetes</collab>
<source><![CDATA[Diretrizes da Sociedade Brasileira de Diabetes 2017-2018]]></source>
<year>2017</year>
<publisher-loc><![CDATA[São Paulo ]]></publisher-loc>
<publisher-name><![CDATA[Clannad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malachias]]></surname>
<given-names><![CDATA[M.V.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[M.A.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Nobre]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Alessi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Feitosa]]></surname>
<given-names><![CDATA[A.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[E.B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diretriz Brasileira de Hipertensão Arterial]]></article-title>
<source><![CDATA[Arq. Bras. Cardiol]]></source>
<year>2016</year>
<volume>107</volume>
<numero>^s3</numero>
<edition>7a</edition>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>1-83</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<source><![CDATA[JAMA]]></source>
<year>2001</year>
<volume>285</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2486-97</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Obesity: preventing and managing the global epidemic]]></source>
<year>2000</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Core Team]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[R: A language and environment for statistical computing]]></source>
<year>2015</year>
<publisher-name><![CDATA[R Foundation for Statistical Computing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuso]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediabetes and lifestyle modification: time to prevent a preventable disease]]></article-title>
<source><![CDATA[Perm. J]]></source>
<year>2014</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>88-93</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[J.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[R.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[T.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L.Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[X.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis]]></article-title>
<source><![CDATA[J. Clin. Pharm. Ther]]></source>
<year>2018</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>556-70</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rha]]></surname>
<given-names><![CDATA[S.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[B.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[H.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[S.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[K.Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of statin use on development of new-onset diabetes mellitus in Asian population]]></article-title>
<source><![CDATA[Am. J. Cardiol]]></source>
<year>2016</year>
<volume>117</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>382-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currie]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Mangin]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Williman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[McKinnon-Gee]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bridgford]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2013</year>
<volume>3</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macedo]]></surname>
<given-names><![CDATA[A.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Douglas]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Smeeth]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Forbes]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ebrahim]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice research datalink]]></article-title>
<source><![CDATA[BMC Cardiovasc. Disord]]></source>
<year>2014</year>
<volume>14</volume>
<numero>85</numero>
<issue>85</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laakso]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuusisto]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes secondary to treatment with statins]]></article-title>
<source><![CDATA[Curr. Diab. Rep]]></source>
<year>2017</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>10</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Preiss]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[H.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Welsh]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[B.M.]]></given-names>
</name>
<name>
<surname><![CDATA[de Craen]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>375</volume>
<numero>9716</numero>
<issue>9716</issue>
<page-range>735-42</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Betteridge]]></surname>
<given-names><![CDATA[D.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Carmena]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diabetogenic action of statins-mechanisms and clinical implications]]></article-title>
<source><![CDATA[Nat. Rev. Endocrinol]]></source>
<year>2016</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>99-110</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
